While pre‐clinical data indicate the requirement for PI3K pathway activity for the survival and proliferation of PTEN‐null TNBC cells, clinical evidence suggests the need to inhibit additional targets to enhance the effect of PI3K pathway inhibitors, widen their therapeutic window, reduce their toxicity, and produce a sustained anti‐tumor effect. The gene discussed is PTEN; the disease is neoplasm.